Seeing the Invisible: Why Single-Cell Science Matters
For over a century, biomedical research has studied disease at the tissue level β examining biopsies, blood samples, and organ systems to understand what goes wrong when illness strikes. While this approach has yielded enormous insights, it inevitably obscures the extraordinary diversity that exists within any given tissue. A tumour biopsy, for example, contains not just cancer cells but a complex ecosystem of immune cells, stromal cells, blood vessel cells, and more, each playing distinct roles in disease progression and treatment response.
Single-cell science is changing this paradigm. By enabling researchers to analyse gene expression, protein activity, and epigenetic states in individual cells, single-cell technologies are revealing the hidden complexity of disease with unprecedented resolution. At GSK, these technologies are transforming how scientists discover drugs, identify therapeutic targets, and understand why patients respond differently to the same treatment.
The Technology Behind the Revolution
Single-cell RNA sequencing (scRNA-seq) sits at the heart of this revolution. Unlike bulk RNA sequencing, which averages gene expression across millions of cells, scRNA-seq captures the transcriptome of each individual cell, producing a high-dimensional portrait of cellular diversity within a tissue sample. Complementary technologies, including single-cell ATAC-seq (for chromatin accessibility), CITE-seq (for simultaneous protein and RNA measurement), and spatial transcriptomics (which preserves the physical location of cells within tissue), further enrich this picture.
The data generated by these approaches are immense β a single experiment can profile tens of thousands to millions of individual cells. Advanced computational methods, including machine learning and artificial intelligence, are essential for processing, clustering, and interpreting these datasets, identifying rare cell populations, tracing developmental trajectories, and mapping cell-to-cell communication networks.
Applications in Drug Discovery
At GSK, single-cell science is being applied across multiple therapeutic areas to accelerate drug discovery and improve clinical outcomes. Key applications include:
- Target identification: By mapping which genes are expressed in specific cell types within diseased tissue, researchers can identify novel drug targets with greater precision, reducing the risk of off-target effects.
- Biomarker discovery: Single-cell profiling of patient samples can reveal cellular signatures that predict treatment response, enabling more effective patient stratification in clinical trials.
- Mechanism of action studies: Understanding how a drug affects individual cell populations helps researchers optimise dosing, predict side effects, and design combination therapies.
- Immune cell characterisation: In immuno-oncology and autoimmune disease, single-cell analysis of immune cell subsets β including T cells, B cells, macrophages, and dendritic cells β provides critical insights into the mechanisms of immune evasion, activation, and exhaustion.
Mapping Eosinophils and Inflammatory Disease
One area where single-cell science is proving particularly impactful at GSK is in understanding the role of eosinophils in inflammatory and allergic diseases. Eosinophils are white blood cells that play a central role in conditions such as severe asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps. Traditionally viewed as a relatively homogeneous cell type, single-cell studies have revealed surprising diversity within the eosinophil population, with distinct subsets exhibiting different functional properties and tissue-specific behaviours.
These insights are informing the development of targeted therapies that modulate specific eosinophil subsets rather than broadly depleting them, an approach that could improve efficacy while reducing the risk of immunosuppression. GSKβs deep expertise in respiratory medicine and immune-system science positions the company uniquely to translate these discoveries into meaningful clinical advances.
Collaboration and the Open Science Movement
GSK has been an active participant in international single-cell initiatives, including the Human Cell Atlas project, which aims to create a comprehensive reference map of every cell type in the human body. By contributing data, computational tools, and scientific expertise to these collaborative efforts, GSK is helping to build a shared resource that will benefit the entire biomedical research community.
This commitment to open science reflects a broader philosophy at GSK: that the most impactful discoveries emerge when organisations work together across traditional boundaries. Whether partnering with academic institutions, technology companies, or public health organisations, GSK believes that collaboration is essential to translating single-cell science from laboratory insights into patient benefits.
The Future of Cellular Medicine
Single-cell science is still in its early stages, but its potential to transform medicine is immense. As technologies become more affordable, faster, and more accessible, single-cell analysis will increasingly become a standard tool in drug development, clinical diagnostics, and personalised medicine. At GSK, the investment in single-cell capabilities is part of a broader strategy to harness advanced technologies β including AI, genomics, and functional genetics β to discover and develop medicines that make a real difference to patientsβ lives.